Back to results

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

Primary Purpose

Pulmonary Disease, Chronic Obstructive

Status

Completed

Phase

Phase 4

Locations

International

Study Type

Interventional

Intervention

Tiotropium bromide

Salmeterol

Placebo Salmeterol

Placebo Tiotropium

About this trial

This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

All patients must have a diagnosis of chronic obstructive pulmonary disease (COPD) and must meet the following criteria at Visit 1:
Patients must have relatively stable, moderate to very severe airway obstruction with a post-bronchodilator FEV1 <=70% of predicted normal and FEV1 <=70% of FVC post-bronchodilator (i.e. 30 minutes after inhalation of 4 puffs of 100 µg salbutamol or equivalent SABA). Predicted normal values will be calculated according to ECSC.
For Height measured in inches Males: FEV1 predicted (L) = 4.30 x (height (inches) / 39.37)-0.029 x age (yrs) - 2.49 Females:FEV1 predicted (L) = 3.95 x (height (inches) / 39.37)-0.025 x age (yrs) - 2.60 For Height measured in metres Males: FEV1 predicted (L) = 4.30 x (height (metres)) - 0.029 x age (years) - 2.49 Females: FEV1 predicted (L) = 3.95 x (height (metres)) - 0.025 x age (years) - 2.60
All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial.
Male or female patients 40 years of age or older.
Patients with a history of at least one exacerbation within the past year requiring treatment with either antibiotics and/or systemic steroids and/or hospitalisation.
Patients must be current or ex-smokers with a smoking history of >= 10 pack-years. (Patients who have never smoked cigarettes must be excluded.)
Patients must be able to perform all study-related procedures including technically acceptable pulmonary function tests (PFTs).
Patients must be able to inhale medication in a competent manner from the HandiHaler and a metered dose inhaler (MDI).
Patients must be able to maintain records (patient daily diary card) during the study period as required in the protocol.

Exclusion Criteria:

Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the patients' ability to participate in the study.
Patients with a diagnosis of asthma.
Patients with a life-threatening pulmonary obstruction, or a history of cystic fibrosis.
Patients with known active tuberculosis.
Patients with a known symptomatic prostatic hyperplasia or bladder neck obstruction. Patients with symptomatically-controlled prostatic hyperplasia on medication may be included and should continue their medication.
Patients with known narrow-angle glaucoma.
Patients with a history of myocardial infarction within the year prior to Visit 1.
Patients with a history of hospital admission for heart failure within the year prior to Visit 1.
Patients with cardiac arrhythmia requiring medical or surgical treatment.
Patients with severe cardiovascular disorders.
Patients with a known hypersensitivity to anticholinergic drugs, beta-adrenergics, lactose or any other component of the medication delivery system.
Patients with known moderate or severe renal insufficiency (known creatinine clearance of <= 50 mL/min).
Patients with untreated known hypokalaemia.
Patients with untreated known thyrotoxicosis.
Patients with brittle/unstable diabetes mellitus.
Patients with a history of and/or active significant alcohol or drug abuse. See exclusion criterion 1.
Patients who have taken an investigational drug within 30 days or six half-lives (whichever is greater) prior to Screening Visit (Visit 1).
Use of systemic corticosteroid medication at unstable doses (i.e less than six weeks on stable dose) or at doses in excess of the equivalent of 10 mg prednisolone per day or 20 mg every other day.
Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e oral contraceptives, intrauterine devices, diaphragm or subdermal implants e.g Norplant) for at least three months prior to, and for the duration of the trial.
Previous participation (receipt of randomised treatment) in this study.
Patients who are currently participating in another study.
Patients with any respiratory infection or COPD exacerbation in the four weeks prior to the Screening Visit (Visit 1) or during the run-in period should be postponed. In the case of a respiratory infection or COPD exacerbation during the run-in period, the latter may be extended up to four weeks.

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Arm Label

Tiotropium + Placebo

Salmeterol + Placebo

Arm Description

patients inhale Tiotropium 18mcg once daily via HandiHaler and Placebo MDI twice daily

patients inhale Salmeterol 50mcg twice daily via MDI and Placebo HandiHaler once daily

Outcomes

Primary Outcome Measures

First Occurrence of (Moderate or Severe) COPD Exacerbation

First occurrence analysed by Cox regression as time to first exacerbation and reported as hazard ratio. An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

Secondary Outcome Measures

COPD Exacerbations Per Patient-year Leading to Hospitalisation

An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

Number of Participants With at Least One COPD Exacerbation

COPD Exacerbations Per Patient-year

First Occurrence of COPD Exacerbation Leading to Hospitalization

First occurrence analysed by Cox regression as time to first exacerbation leading to hospitalisation and reported as hazard ratio. An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

Number of Participants With at Least One COPD Exacerbation Leading to Hospitalisation

Occurrence of Premature Discontinuation of Trial Medication

Occurrence analysed by Cox regression as time to premature discontinuation of trial medication and reported as hazard ratio

Number of Participants With Premature Discontinuation of Trial Medication

First Occurrence of COPD Exacerbation or Discontinuation of Trial Medication Because of Worsening of Underlying Disease, Whichever Comes First

First occurrence analysed by Cox regression as time to first exacerbation or discontinuation of trial medication because of worsening of underlying disease, whichever comes first and reported as hazard ratio. An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

First Occurrence of COPD Exacerbations Treated With Systemic Steroids

First occurrence analysed by Cox regression as time to first exacerbation treated with systemic steroids and reported as hazard ratio. An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

First Occurrence of COPD Exacerbations Treated With Antibiotics

First occurrence analysed by Cox regression as time to first exacerbation treated with antibiotics and reported as hazard ratio. An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

First Occurrence of COPD Exacerbations Treated With Systemic Steroids and Antibiotics

First occurrence analysed by Cox regression as time to first exacerbation treated with systemic steroids and antibiotics and reported as hazard ratio. An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

COPD Exacerbations Treated With Systemic Steroids Per Patient-year

COPD Exacerbations Treated With Antibiotics Per Patient-year

COPD Exacerbations Treated With Systemic Steroids and Antibiotics Per Patient-year

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 1

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 2

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 3

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 4

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 5

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 6

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 7

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 8

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 9

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 10

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 11

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 12

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 13

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 14

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 15

PEFR means peak expiratory flow rate and is measured in liter per minute

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 16

PEFR means peak expiratory flow rate and is measured in liter per minute

Full Information

NCT ID

NCT00563381

First Posted

November 22, 2007

Last Updated

November 27, 2013

Sponsor

Boehringer Ingelheim

Collaborators

Pfizer

1. Study Identification

Unique Protocol Identification Number

NCT00563381

Brief Title

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

Official Title

Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).

Study Type

Interventional

2. Study Status

Record Verification Date

July 2012

Overall Recruitment Status

Completed

Study Start Date

January 2008 (undefined)

Primary Completion Date

April 2010 (Actual)

Study Completion Date

undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor

Boehringer Ingelheim

Collaborators

Pfizer

4. Oversight

5. Study Description

Brief Summary

This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD. There will be a two-week run-in period followed by a 52-week randomised treatment phase. Patients who withdraw prematurely from trial medication will be encouraged to remain in the trial and participate in follow-up telephone contacts until their predicted normal exit date from the trial (i.e. 52 weeks after taking the first dose of randomised treatment). The phone calls will be made at all scheduled visits. The primary objective of this study is to compare the effect of tiotropium (18 mcg) inhalation capsule via HandiHaler with that of salmeterol (50 mcg) via MDI on COPD exacerbations. The primary endpoint is time to first COPD exacerbation during the 52 week randomised treatment period. A COPD exacerbation will be defined as a complex of respiratory events / symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnoea or chest tightness with at least one symptom lasting at least three days requiring treatment with antibiotics and/or systemic steroids and/or hospitalisation. The onset of an exacerbation is defined as the onset of the first new or increased reported symptom. The end of the exacerbation should be recorded as defined by the investigator. Only COPD exacerbations with onset during randomised treatment will be included in the analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Pulmonary Disease, Chronic Obstructive

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 4

Interventional Study Model

Parallel Assignment

Masking

Double

Allocation

Randomized

Enrollment

7376 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Tiotropium + Placebo

Arm Type

Active Comparator

Arm Description

patients inhale Tiotropium 18mcg once daily via HandiHaler and Placebo MDI twice daily

Arm Title

Salmeterol + Placebo

Arm Type

Active Comparator

Arm Description

patients inhale Salmeterol 50mcg twice daily via MDI and Placebo HandiHaler once daily

Intervention Type

Drug

Intervention Name(s)

Tiotropium bromide

Intervention Description

18 mcg/daily

Intervention Type

Drug

Intervention Name(s)

Salmeterol

Intervention Description

100 mcg/daily

Intervention Type

Drug

Intervention Name(s)

Placebo Salmeterol

Intervention Description

Placebo identical to Salmeterol device

Intervention Type

Drug

Intervention Name(s)

Placebo Tiotropium

Intervention Description

Placebo identical to Tiotropium device

Primary Outcome Measure Information:

Title

First Occurrence of (Moderate or Severe) COPD Exacerbation

Description

Time Frame

52 weeks

Secondary Outcome Measure Information:

Title

COPD Exacerbations Per Patient-year Leading to Hospitalisation

Description

Time Frame

52 weeks

Title

Number of Participants With at Least One COPD Exacerbation

Description

Time Frame

52 weeks

Title

COPD Exacerbations Per Patient-year

Time Frame

52 weeks

Title

First Occurrence of COPD Exacerbation Leading to Hospitalization

Description

Time Frame

52 weeks

Title

Number of Participants With at Least One COPD Exacerbation Leading to Hospitalisation

Description

Time Frame

52 weeks

Title

Occurrence of Premature Discontinuation of Trial Medication

Description

Occurrence analysed by Cox regression as time to premature discontinuation of trial medication and reported as hazard ratio

Time Frame

52 weeks

Title

Number of Participants With Premature Discontinuation of Trial Medication

Time Frame

52 weeks

Title

First Occurrence of COPD Exacerbation or Discontinuation of Trial Medication Because of Worsening of Underlying Disease, Whichever Comes First

Description

Time Frame

52 weeks

Title

First Occurrence of COPD Exacerbations Treated With Systemic Steroids

Description

Time Frame

52 weeks

Title

First Occurrence of COPD Exacerbations Treated With Antibiotics

Description

Time Frame

52 weeks

Title

First Occurrence of COPD Exacerbations Treated With Systemic Steroids and Antibiotics

Description

Time Frame

52 weeks

Title

COPD Exacerbations Treated With Systemic Steroids Per Patient-year

Description

Time Frame

52 weeks

Title

COPD Exacerbations Treated With Antibiotics Per Patient-year

Description

Time Frame

52 weeks

Title

COPD Exacerbations Treated With Systemic Steroids and Antibiotics Per Patient-year

Description

Time Frame

52 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 1

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 2

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 3

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 4

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 5

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 6

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 7

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 8

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 9

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 10

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 11

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 12

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 13

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 14

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 15

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

Title

Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 16

Description

PEFR means peak expiratory flow rate and is measured in liter per minute

Time Frame

16 weeks

10. Eligibility

Sex

All

Minimum Age & Unit of Time

40 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: All patients must have a diagnosis of chronic obstructive pulmonary disease (COPD) and must meet the following criteria at Visit 1: Patients must have relatively stable, moderate to very severe airway obstruction with a post-bronchodilator FEV1 <=70% of predicted normal and FEV1 <=70% of FVC post-bronchodilator (i.e. 30 minutes after inhalation of 4 puffs of 100 µg salbutamol or equivalent SABA). Predicted normal values will be calculated according to ECSC. For Height measured in inches Males: FEV1 predicted (L) = 4.30 x (height (inches) / 39.37)-0.029 x age (yrs) - 2.49 Females:FEV1 predicted (L) = 3.95 x (height (inches) / 39.37)-0.025 x age (yrs) - 2.60 For Height measured in metres Males: FEV1 predicted (L) = 4.30 x (height (metres)) - 0.029 x age (years) - 2.49 Females: FEV1 predicted (L) = 3.95 x (height (metres)) - 0.025 x age (years) - 2.60 All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial. Male or female patients 40 years of age or older. Patients with a history of at least one exacerbation within the past year requiring treatment with either antibiotics and/or systemic steroids and/or hospitalisation. Patients must be current or ex-smokers with a smoking history of >= 10 pack-years. (Patients who have never smoked cigarettes must be excluded.) Patients must be able to perform all study-related procedures including technically acceptable pulmonary function tests (PFTs). Patients must be able to inhale medication in a competent manner from the HandiHaler and a metered dose inhaler (MDI). Patients must be able to maintain records (patient daily diary card) during the study period as required in the protocol. Exclusion Criteria: Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the patients' ability to participate in the study. Patients with a diagnosis of asthma. Patients with a life-threatening pulmonary obstruction, or a history of cystic fibrosis. Patients with known active tuberculosis. Patients with a known symptomatic prostatic hyperplasia or bladder neck obstruction. Patients with symptomatically-controlled prostatic hyperplasia on medication may be included and should continue their medication. Patients with known narrow-angle glaucoma. Patients with a history of myocardial infarction within the year prior to Visit 1. Patients with a history of hospital admission for heart failure within the year prior to Visit 1. Patients with cardiac arrhythmia requiring medical or surgical treatment. Patients with severe cardiovascular disorders. Patients with a known hypersensitivity to anticholinergic drugs, beta-adrenergics, lactose or any other component of the medication delivery system. Patients with known moderate or severe renal insufficiency (known creatinine clearance of <= 50 mL/min). Patients with untreated known hypokalaemia. Patients with untreated known thyrotoxicosis. Patients with brittle/unstable diabetes mellitus. Patients with a history of and/or active significant alcohol or drug abuse. See exclusion criterion 1. Patients who have taken an investigational drug within 30 days or six half-lives (whichever is greater) prior to Screening Visit (Visit 1). Use of systemic corticosteroid medication at unstable doses (i.e less than six weeks on stable dose) or at doses in excess of the equivalent of 10 mg prednisolone per day or 20 mg every other day. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e oral contraceptives, intrauterine devices, diaphragm or subdermal implants e.g Norplant) for at least three months prior to, and for the duration of the trial. Previous participation (receipt of randomised treatment) in this study. Patients who are currently participating in another study. Patients with any respiratory infection or COPD exacerbation in the four weeks prior to the Screening Visit (Visit 1) or during the run-in period should be postponed. In the case of a respiratory infection or COPD exacerbation during the run-in period, the latter may be extended up to four weeks.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Boehringer Ingelheim

Organizational Affiliation

Boehringer Ingelheim

Official's Role

Study Chair

Facility Information:

Facility Name

205.389.1020 Boehringer Ingelheim Investigational Site

City

Feldbach

Country

Austria

Facility Name

205.389.1010 Boehringer Ingelheim Investigational Site

City

Feldkirch

Country

Austria

Facility Name

205.389.1011 Boehringer Ingelheim Investigational Site

City

Grimmenstein/Hochegg

Country

Austria

Facility Name

205.389.1003 Boehringer Ingelheim Investigational Site

City

Gänserndorf

Country

Austria

Facility Name

205.389.1005 Boehringer Ingelheim Investigational Site

City

Hallein

Country

Austria

Facility Name

205.389.1023 Boehringer Ingelheim Investigational Site

City

Linz

Country

Austria

Facility Name

205.389.1001 Boehringer Ingelheim Investigational Site

City

Mittersill

Country

Austria

Facility Name

205.389.1027 Boehringer Ingelheim Investigational Site

City

Salzburg

Country

Austria

Facility Name

205.389.1026 Boehringer Ingelheim Investigational Site

City

Schlüßlberg

Country

Austria

Facility Name

205.389.1016 Boehringer Ingelheim Investigational Site

City

Spittal/Drau

Country

Austria

Facility Name

205.389.1022 Boehringer Ingelheim Investigational Site

City

Steyr

Country

Austria

Facility Name

205.389.1002 Boehringer Ingelheim Investigational Site

City

Wien

Country

Austria

Facility Name

205.389.1006 Boehringer Ingelheim Investigational Site

City

Wien

Country

Austria

Facility Name

205.389.1014 Boehringer Ingelheim Investigational Site

City

Wien

Country

Austria

Facility Name

205.389.1018 Boehringer Ingelheim Investigational Site

City

Wien

Country

Austria

Facility Name

205.389.1021 Boehringer Ingelheim Investigational Site

City

Wien

Country

Austria

Facility Name

205.389.1029 Boehringer Ingelheim Investigational Site

City

Wien

Country

Austria

Facility Name

205.389.1017 Boehringer Ingelheim Investigational Site

City

Zwettl

Country

Austria

Facility Name

205.389.1120 Boehringer Ingelheim Investigational Site

City

Buizingen

Country

Belgium

Facility Name

205.389.1124 Boehringer Ingelheim Investigational Site

City

Cerexhe Heuseux

Country

Belgium

Facility Name

205.389.1116 Boehringer Ingelheim Investigational Site

City

Chenée (Liége)

Country

Belgium

Facility Name

205.389.1121 Boehringer Ingelheim Investigational Site

City

Dour

Country

Belgium

Facility Name

205.389.1113 Boehringer Ingelheim Investigational Site

City

Gembloux

Country

Belgium

Facility Name

205.389.1117 Boehringer Ingelheim Investigational Site

City

Gozée

Country

Belgium

Facility Name

205.389.1126 Boehringer Ingelheim Investigational Site

City

Hasselt

Country

Belgium

Facility Name

205.389.1129 Boehringer Ingelheim Investigational Site

City

Natoye

Country

Belgium

Facility Name

205.389.1130 Boehringer Ingelheim Investigational Site

City

Quaregnon

Country

Belgium

Facility Name

205.389.1115 Boehringer Ingelheim Investigational Site

City

Thuillies

Country

Belgium

Facility Name

205.389.1107 Boehringer Ingelheim Investigational Site

City

Wetteren

Country

Belgium

Facility Name

205.389.3911 Boehringer Ingelheim Investigational Site

City

Pazardjik

Country

Bulgaria

Facility Name

205.389.3903 Boehringer Ingelheim Investigational Site

City

Plovdiv

Country

Bulgaria

Facility Name

205.389.3915 Boehringer Ingelheim Investigational Site

City

Plovdiv

Country

Bulgaria

Facility Name

205.389.3918 Boehringer Ingelheim Investigational Site

City

Rousse

Country

Bulgaria

Facility Name

205.389.3914 Boehringer Ingelheim Investigational Site

City

Sliven

Country

Bulgaria

Facility Name

205.389.3902 Boehringer Ingelheim Investigational Site

City

Sofia

Country

Bulgaria

Facility Name

205.389.3906 Boehringer Ingelheim Investigational Site

City

Sofia

Country

Bulgaria

Facility Name

205.389.3907 Boehringer Ingelheim Investigational Site

City

Sofia

Country

Bulgaria

Facility Name

205.389.3908 Boehringer Ingelheim Investigational Site

City

Stara Zagora

Country

Bulgaria

Facility Name

205.389.3916 Boehringer Ingelheim Investigational Site

City

Troyan

Country

Bulgaria

Facility Name

205.389.3912 Boehringer Ingelheim Investigational Site

City

Varna

Country

Bulgaria

Facility Name

205.389.3901 Boehringer Ingelheim Investigational Site

City

Veliko Turnovo

Country

Bulgaria

Facility Name

205.389.1211 Boehringer Ingelheim Investigational Site

City

Benesov

Country

Czech Republic

Facility Name

205.389.1213 Boehringer Ingelheim Investigational Site

City

Beroun

Country

Czech Republic

Facility Name

205.389.1220 Boehringer Ingelheim Investigational Site

City

Beroun

Country

Czech Republic

Facility Name

205.389.1204 Boehringer Ingelheim Investigational Site

City

Brno-Kralovo Pole

Country

Czech Republic

Facility Name

205.389.1212 Boehringer Ingelheim Investigational Site

City

Cheb

Country

Czech Republic

Facility Name

205.389.1205 Boehringer Ingelheim Investigational Site

City

Havlickuv Brod

Country

Czech Republic

Facility Name

205.389.1230 Boehringer Ingelheim Investigational Site

City

Humpolec

Country

Czech Republic

Facility Name

205.389.1208 Boehringer Ingelheim Investigational Site

City

Jaromer

Country

Czech Republic

Facility Name

205.389.1219 Boehringer Ingelheim Investigational Site

City

Kyjov

Country

Czech Republic

Facility Name

205.389.1225 Boehringer Ingelheim Investigational Site

City

Liberec

Country

Czech Republic

Facility Name

205.389.1218 Boehringer Ingelheim Investigational Site

City

Litomerice

Country

Czech Republic

Facility Name

205.389.1214 Boehringer Ingelheim Investigational Site

City

Lovosice

Country

Czech Republic

Facility Name

205.389.1207 Boehringer Ingelheim Investigational Site

City

Neratovice

Country

Czech Republic

Facility Name

205.389.1222 Boehringer Ingelheim Investigational Site

City

Ostrava

Country

Czech Republic

Facility Name

205.389.1209 Boehringer Ingelheim Investigational Site

City

Plzen

Country

Czech Republic

Facility Name

205.389.1216 Boehringer Ingelheim Investigational Site

City

Plzen

Country

Czech Republic

Facility Name

205.389.1217 Boehringer Ingelheim Investigational Site

City

Praha 13

Country

Czech Republic

Facility Name

205.389.1215 Boehringer Ingelheim Investigational Site

City

Praha 17

Country

Czech Republic

Facility Name

205.389.1232 Boehringer Ingelheim Investigational Site

City

Praha 3

Country

Czech Republic

Facility Name

205.389.1229 Boehringer Ingelheim Investigational Site

City

Praha 4

Country

Czech Republic

Facility Name

205.389.1223 Boehringer Ingelheim Investigational Site

City

Praha 5

Country

Czech Republic

Facility Name

205.389.1227 Boehringer Ingelheim Investigational Site

City

Praha 5

Country

Czech Republic

Facility Name

205.389.1224 Boehringer Ingelheim Investigational Site

City

Praha 6 - Brevnov

Country

Czech Republic

Facility Name

205.389.1228 Boehringer Ingelheim Investigational Site

City

Prerov

Country

Czech Republic

Facility Name

205.389.1231 Boehringer Ingelheim Investigational Site

City

Rokycany

Country

Czech Republic

Facility Name

205.389.1221 Boehringer Ingelheim Investigational Site

City

Strakonice

Country

Czech Republic

Facility Name

205.389.1206 Boehringer Ingelheim Investigational Site

City

Tremosna

Country

Czech Republic

Facility Name

205.389.1201 Boehringer Ingelheim Investigational Site

City

Zatec

Country

Czech Republic

Facility Name

205.389.1210 Boehringer Ingelheim Investigational Site

City

Znojmo

Country

Czech Republic

Facility Name

205.389.1304 Boehringer Ingelheim Investigational Site

City

Copenhagen

Country

Denmark

Facility Name

205.389.1309 Boehringer Ingelheim Investigational Site

City

Frederikssund

Country

Denmark

Facility Name

205.389.1301 Boehringer Ingelheim Investigational Site

City

Helsingor

Country

Denmark

Facility Name

205.389.1308 Boehringer Ingelheim Investigational Site

City

Helsingør

Country

Denmark

Facility Name

205.389.1311 Boehringer Ingelheim Investigational Site

City

Holstebro

Country

Denmark

Facility Name

205.389.1302 Boehringer Ingelheim Investigational Site

City

Næstved

Country

Denmark

Facility Name

205.389.1303 Boehringer Ingelheim Investigational Site

City

Roskilde

Country

Denmark

Facility Name

205.389.1310 Boehringer Ingelheim Investigational Site

City

Skive

Country

Denmark

Facility Name

205.389.1312 Boehringer Ingelheim Investigational Site

City

Sonderborg

Country

Denmark

Facility Name

205.389.1307 Boehringer Ingelheim Investigational Site

City

Værløse

Country

Denmark

Facility Name

205.389.1402 Boehringer Ingelheim Investigational Site

City

Helsinki

Country

Finland

Facility Name

205.389.1416 Boehringer Ingelheim Investigational Site

City

Hyvinkää

Country

Finland

Facility Name

205.389.1410 Boehringer Ingelheim Investigational Site

City

Jyväskylä

Country

Finland

Facility Name

205.389.1404 Boehringer Ingelheim Investigational Site

City

Lahti

Country

Finland

Facility Name

205.389.1417 Boehringer Ingelheim Investigational Site

City

Lappeenranta

Country

Finland

Facility Name

205.389.1415 Boehringer Ingelheim Investigational Site

City

Lohja

Country

Finland

Facility Name

205.389.1411 Boehringer Ingelheim Investigational Site

City

Mikkeli

Country

Finland

Facility Name

205.389.1409 Boehringer Ingelheim Investigational Site

City

Pori

Country

Finland

Facility Name

205.389.1412 Boehringer Ingelheim Investigational Site

City

Preitilä Paimio

Country

Finland

Facility Name

205.389.1407 Boehringer Ingelheim Investigational Site

City

Turku

Country

Finland

Facility Name

205.389.1607 Boehringer Ingelheim Investigational Site

City

Bauge

Country

France

Facility Name

205.389.1525 Boehringer Ingelheim Investigational Site

City

Beauvais

Country

France

Facility Name

205.389.1523 Boehringer Ingelheim Investigational Site

City

Bethune

Country

France

Facility Name

205.389.1571 Boehringer Ingelheim Investigational Site

City

Cestas

Country

France

Facility Name

205.389.1561 Boehringer Ingelheim Investigational Site

City

Charry le Rouet

Country

France

Facility Name

205.389.1507 Boehringer Ingelheim Investigational Site

City

Cholet

Country

France

Facility Name

205.389.1606 Boehringer Ingelheim Investigational Site

City

Ecouflant

Country

France

Facility Name

205.389.1554 Boehringer Ingelheim Investigational Site

City

Ermont

Country

France

Facility Name

205.389.1597 Boehringer Ingelheim Investigational Site

City

La Barre de Monts

Country

France

Facility Name

205.389.1581 Boehringer Ingelheim Investigational Site

City

La Jubaudière

Country

France

Facility Name

205.389.1536 Boehringer Ingelheim Investigational Site

City

La Roche Sur Yon

Country

France

Facility Name

205.389.1598 Boehringer Ingelheim Investigational Site

City

La Roche sur Yon

Country

France

Facility Name

205.389.1501 Boehringer Ingelheim Investigational Site

City

Le Kremlin Bicetre

Country

France

Facility Name

205.389.1503 Boehringer Ingelheim Investigational Site

City

Le Mans Cedex

Country

France

Facility Name

205.389.1586 Boehringer Ingelheim Investigational Site

City

Le Pradet

Country

France

Facility Name

205.389.1528 Boehringer Ingelheim Investigational Site

City

Marseille

Country

France

Facility Name

205.389.1530 Boehringer Ingelheim Investigational Site

City

Marseille

Country

France

Facility Name

205.389.1558 Boehringer Ingelheim Investigational Site

City

Marseille

Country

France

Facility Name

205.389.1564 Boehringer Ingelheim Investigational Site

City

Marseille

Country

France

Facility Name

205.389.1565 Boehringer Ingelheim Investigational Site

City

Marseille

Country

France

Facility Name

205.389.1539 Boehringer Ingelheim Investigational Site

City

Montfermeil

Country

France

Facility Name

205.389.1608 Boehringer Ingelheim Investigational Site

City

Nantes

Country

France

Facility Name

205.389.1526 Boehringer Ingelheim Investigational Site

City

Nice

Country

France

Facility Name

205.389.1504 Boehringer Ingelheim Investigational Site

City

Nimes

Country

France

Facility Name

205.389.1502 Boehringer Ingelheim Investigational Site

City

Ollioules

Country

France

Facility Name

205.389.1541 Boehringer Ingelheim Investigational Site

City

Orleans

Country

France

Facility Name

205.389.1527 Boehringer Ingelheim Investigational Site

City

Perpignan

Country

France

Facility Name

205.389.1532 Boehringer Ingelheim Investigational Site

City

PIERRE BENITE cédex

Country

France

Facility Name

205.389.1553 Boehringer Ingelheim Investigational Site

City

Rennes cedex 9

Country

France

Facility Name

205.389.1555 Boehringer Ingelheim Investigational Site

City

Saint Dié des Vosges

Country

France

Facility Name

205.389.1575 Boehringer Ingelheim Investigational Site

City

Saint Germain du Puch

Country

France

Facility Name

205.389.1547 Boehringer Ingelheim Investigational Site

City

Saint Laurent du Var

Country

France

Facility Name

205.389.1572 Boehringer Ingelheim Investigational Site

City

Saint Laurent

Country

France

Facility Name

205.389.1567 Boehringer Ingelheim Investigational Site

City

Saint Orens de Cameville

Country

France

Facility Name

205.389.1577 Boehringer Ingelheim Investigational Site

City

Saint Pierre Montlimard

Country

France

Facility Name

205.389.1531 Boehringer Ingelheim Investigational Site

City

Saint Quentin

Country

France

Facility Name

205.389.1569 Boehringer Ingelheim Investigational Site

City

Seysses

Country

France

Facility Name

205.389.1514 Boehringer Ingelheim Investigational Site

City

St-Etienne

Country

France

Facility Name

205.389.1510 Boehringer Ingelheim Investigational Site

City

Strasbourg

Country

France

Facility Name

205.389.1522 Boehringer Ingelheim Investigational Site

City

Strasbourg

Country

France

Facility Name

205.389.1520 Boehringer Ingelheim Investigational Site

City

Sélestat

Country

France

Facility Name

205.389.1512 Boehringer Ingelheim Investigational Site

City

Toulon

Country

France

Facility Name

205.389.1515 Boehringer Ingelheim Investigational Site

City

Toulon

Country

France

Facility Name

205.389.1519 Boehringer Ingelheim Investigational Site

City

Toulon

Country

France

Facility Name

205.389.1588 Boehringer Ingelheim Investigational Site

City

Toulon

Country

France

Facility Name

205.389.1589 Boehringer Ingelheim Investigational Site

City

Toulon

Country

France

Facility Name

205.389.1590 Boehringer Ingelheim Investigational Site

City

Toulon

Country

France

Facility Name

205.389.1595 Boehringer Ingelheim Investigational Site

City

Toulon

Country

France

Facility Name

205.389.1542 Boehringer Ingelheim Investigational Site

City

Toulouse

Country

France

Facility Name

205.389.1574 Boehringer Ingelheim Investigational Site

City

Villenave D'ornon

Country

France

Facility Name

205.389.1741 Boehringer Ingelheim Investigational Site

City

Aachen

Country

Germany

Facility Name

205.389.1857 Boehringer Ingelheim Investigational Site

City

Aalen

Country

Germany

Facility Name

205.389.1934 Boehringer Ingelheim Investigational Site

City

Auerbach

Country

Germany

Facility Name

205.389.1868 Boehringer Ingelheim Investigational Site

City

Augsburg

Country

Germany

Facility Name

205.389.1887 Boehringer Ingelheim Investigational Site

City

Augsburg

Country

Germany

Facility Name

205.389.1707 Boehringer Ingelheim Investigational Site

City

Bad Lippspringe

Country

Germany

Facility Name

205.389.1722 Boehringer Ingelheim Investigational Site

City

Bad Pymont

Country

Germany

Facility Name

205.389.1850 Boehringer Ingelheim Investigational Site

City

Bad Wörishofen

Country

Germany

Facility Name

205.389.1765 Boehringer Ingelheim Investigational Site

City

Bahrdorf

Country

Germany

Facility Name

205.389.1792 Boehringer Ingelheim Investigational Site

City

Beckum

Country

Germany

Facility Name

205.389.1801 Boehringer Ingelheim Investigational Site

City

Bensheim

Country

Germany

Facility Name

205.389.1946 Boehringer Ingelheim Investigational Site

City

Bensheim

Country

Germany

Facility Name

205.389.1824 Boehringer Ingelheim Investigational Site

City

Bergisch Gladbach

Country

Germany

Facility Name

205.389.1709 Boehringer Ingelheim Investigational Site

City

Bergkamen

Country

Germany

Facility Name

205.389.1750 Boehringer Ingelheim Investigational Site

City

Berkatal-Frankershausen

Country

Germany

Facility Name

205.389.1701 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1743 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1769 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1789 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1790 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1847 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1855 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1861 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1862 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1867 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1903 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1931 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1932 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1937 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1960 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1969 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1981 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1983 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1984 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.389.1747 Boehringer Ingelheim Investigational Site

City

Bocholt

Country

Germany

Facility Name

205.389.1808 Boehringer Ingelheim Investigational Site

City

Bochum

Country

Germany

Facility Name

205.389.1811 Boehringer Ingelheim Investigational Site

City

Bochum

Country

Germany

Facility Name

205.389.1828 Boehringer Ingelheim Investigational Site

City

Bonn

Country

Germany

Facility Name

205.389.1870 Boehringer Ingelheim Investigational Site

City

Bonn

Country

Germany

Facility Name

205.389.1705 Boehringer Ingelheim Investigational Site

City

Borna

Country

Germany

Facility Name

205.389.1809 Boehringer Ingelheim Investigational Site

City

Brandenburg/Havel

Country

Germany

Facility Name

205.389.1859 Boehringer Ingelheim Investigational Site

City

Bruchsal

Country

Germany

Facility Name

205.389.1734 Boehringer Ingelheim Investigational Site

City

Camburg

Country

Germany

Facility Name

205.389.1923 Boehringer Ingelheim Investigational Site

City

Celle

Country

Germany

Facility Name

205.389.1901 Boehringer Ingelheim Investigational Site

City

Coswig

Country

Germany

Facility Name

205.389.1891 Boehringer Ingelheim Investigational Site

City

Cottbus

Country

Germany

Facility Name

205.389.1858 Boehringer Ingelheim Investigational Site

City

Deggendorf

Country

Germany

Facility Name

205.389.1784 Boehringer Ingelheim Investigational Site

City

Donaueschingen

Country

Germany

Facility Name

205.389.1713 Boehringer Ingelheim Investigational Site

City

Dortmund

Country

Germany

Facility Name

205.389.1706 Boehringer Ingelheim Investigational Site

City

Dresden

Country

Germany

Facility Name

205.389.1967 Boehringer Ingelheim Investigational Site

City

Düren

Country

Germany

Facility Name

205.389.1814 Boehringer Ingelheim Investigational Site

City

Engelskirchen

Country

Germany

Facility Name

205.389.1773 Boehringer Ingelheim Investigational Site

City

Ense

Country

Germany

Facility Name

205.389.1727 Boehringer Ingelheim Investigational Site

City

Eppelborn-Bubach

Country

Germany

Facility Name

205.389.1864 Boehringer Ingelheim Investigational Site

City

Erfurt

Country

Germany

Facility Name

205.389.1940 Boehringer Ingelheim Investigational Site

City

Erlangen

Country

Germany

Facility Name

205.389.1900 Boehringer Ingelheim Investigational Site

City

Eschwege

Country

Germany

Facility Name

205.389.1758 Boehringer Ingelheim Investigational Site

City

Essen

Country

Germany

Facility Name

205.389.1975 Boehringer Ingelheim Investigational Site

City

Essen

Country

Germany

Facility Name

205.389.1982 Boehringer Ingelheim Investigational Site

City

Essen

Country

Germany

Facility Name

205.389.1724 Boehringer Ingelheim Investigational Site

City

Ettlingen

Country

Germany

Facility Name

205.389.1806 Boehringer Ingelheim Investigational Site

City

Feldkirchen-Westerham

Country

Germany

Facility Name

205.389.1976 Boehringer Ingelheim Investigational Site

City

Forchheim

Country

Germany

Facility Name

205.389.1795 Boehringer Ingelheim Investigational Site

City

Frankenberg

Country

Germany

Facility Name

205.389.1905 Boehringer Ingelheim Investigational Site

City

Frankfurt/Main

Country

Germany

Facility Name

205.389.1752 Boehringer Ingelheim Investigational Site

City

Fuldatal-Ihringshausen

Country

Germany

Facility Name

205.389.1943 Boehringer Ingelheim Investigational Site

City

Föhren

Country

Germany

Facility Name

205.389.1971 Boehringer Ingelheim Investigational Site

City

Fürth

Country

Germany

Facility Name

205.389.1766 Boehringer Ingelheim Investigational Site

City

Gars

Country

Germany

Facility Name

205.389.1977 Boehringer Ingelheim Investigational Site

City

Gelsenkirchen

Country

Germany

Facility Name

205.389.1744 Boehringer Ingelheim Investigational Site

City

Georgensgmünd

Country

Germany

Facility Name

205.389.1875 Boehringer Ingelheim Investigational Site

City

Gießen

Country

Germany

Facility Name

205.389.1836 Boehringer Ingelheim Investigational Site

City

Gifhorn

Country

Germany

Facility Name

205.389.1914 Boehringer Ingelheim Investigational Site

City

Goch

Country

Germany

Facility Name

205.389.1886 Boehringer Ingelheim Investigational Site

City

Greiz

Country

Germany

Facility Name

205.389.1768 Boehringer Ingelheim Investigational Site

City

Grünberg

Country

Germany

Facility Name

205.389.1751 Boehringer Ingelheim Investigational Site

City

Göttingen

Country

Germany

Facility Name

205.389.1831 Boehringer Ingelheim Investigational Site

City

Hagen

Country

Germany

Facility Name

205.389.1827 Boehringer Ingelheim Investigational Site

City

Halle

Country

Germany

Facility Name

205.389.1917 Boehringer Ingelheim Investigational Site

City

Hamburg

Country

Germany

Facility Name

205.389.1924 Boehringer Ingelheim Investigational Site

City

Hamburg

Country

Germany

Facility Name

205.389.1925 Boehringer Ingelheim Investigational Site

City

Hamburg

Country

Germany

Facility Name

205.389.1980 Boehringer Ingelheim Investigational Site

City

Hamburg

Country

Germany

Facility Name

205.389.1716 Boehringer Ingelheim Investigational Site

City

Hammah

Country

Germany

Facility Name

205.389.1702 Boehringer Ingelheim Investigational Site

City

Hammelburg

Country

Germany

Facility Name

205.389.1802 Boehringer Ingelheim Investigational Site

City

Hannover

Country

Germany

Facility Name

205.389.1712 Boehringer Ingelheim Investigational Site

City

Harsewinkel

Country

Germany

Facility Name

205.389.1738 Boehringer Ingelheim Investigational Site

City

Hauzenberg

Country

Germany

Facility Name

205.389.1860 Boehringer Ingelheim Investigational Site

City

Hemmingen

Country

Germany

Facility Name

205.389.1949 Boehringer Ingelheim Investigational Site

City

Höchstädt

Country

Germany

Facility Name

205.389.1726 Boehringer Ingelheim Investigational Site

City

Ingelheim

Country

Germany

Facility Name

205.389.1873 Boehringer Ingelheim Investigational Site

City

Karlsruhe

Country

Germany

Facility Name

205.389.1838 Boehringer Ingelheim Investigational Site

City

Kaufbeuren

Country

Germany

Facility Name

205.389.1839 Boehringer Ingelheim Investigational Site

City

Koblenz

Country

Germany

Facility Name

205.389.1881 Boehringer Ingelheim Investigational Site

City

Krefeld

Country

Germany

Facility Name

205.389.1786 Boehringer Ingelheim Investigational Site

City

Krumpa

Country

Germany

Facility Name

205.389.1704 Boehringer Ingelheim Investigational Site

City

Käbschütztal-Krögis

Country

Germany

Facility Name

205.389.1892 Boehringer Ingelheim Investigational Site

City

Köln

Country

Germany

Facility Name

205.389.1974 Boehringer Ingelheim Investigational Site

City

Köln

Country

Germany

Facility Name

205.389.1813 Boehringer Ingelheim Investigational Site

City

Köthen

Country

Germany

Facility Name

205.389.1902 Boehringer Ingelheim Investigational Site

City

Landsberg

Country

Germany

Facility Name

205.389.1837 Boehringer Ingelheim Investigational Site

City

Leipzig

Country

Germany

Facility Name

205.389.1841 Boehringer Ingelheim Investigational Site

City

Leipzig

Country

Germany

Facility Name

205.389.1894 Boehringer Ingelheim Investigational Site

City

Leipzig

Country

Germany

Facility Name

205.389.1908 Boehringer Ingelheim Investigational Site

City

Leipzig

Country

Germany

Facility Name

205.389.1874 Boehringer Ingelheim Investigational Site

City

Leonberg

Country

Germany

Facility Name

205.389.1955 Boehringer Ingelheim Investigational Site

City

Limburg

Country

Germany

Facility Name

205.389.1904 Boehringer Ingelheim Investigational Site

City

Lorch

Country

Germany

Facility Name

205.389.1877 Boehringer Ingelheim Investigational Site

City

Lübeck

Country

Germany

Facility Name

205.389.1823 Boehringer Ingelheim Investigational Site

City

Lützen

Country

Germany

Facility Name

205.389.1879 Boehringer Ingelheim Investigational Site

City

Magdeburg

Country

Germany

Facility Name

205.389.1840 Boehringer Ingelheim Investigational Site

City

Mannheim

Country

Germany

Facility Name

205.389.1978 Boehringer Ingelheim Investigational Site

City

Mannheim

Country

Germany

Facility Name

205.389.1866 Boehringer Ingelheim Investigational Site

City

Marburg

Country

Germany

Facility Name

205.389.1871 Boehringer Ingelheim Investigational Site

City

Marburg

Country

Germany

Facility Name

205.389.1926 Boehringer Ingelheim Investigational Site

City

Marburg

Country

Germany

Facility Name

205.389.1776 Boehringer Ingelheim Investigational Site

City

Marl

Country

Germany

Facility Name

205.389.1779 Boehringer Ingelheim Investigational Site

City

Merrbusch

Country

Germany

Facility Name

205.389.1799 Boehringer Ingelheim Investigational Site

City

München

Country

Germany

Facility Name

205.389.1815 Boehringer Ingelheim Investigational Site

City

München

Country

Germany

Facility Name

205.389.1817 Boehringer Ingelheim Investigational Site

City

München

Country

Germany

Facility Name

205.389.1843 Boehringer Ingelheim Investigational Site

City

München

Country

Germany

Facility Name

205.389.1952 Boehringer Ingelheim Investigational Site

City

Neubrandenburg

Country

Germany

Facility Name

205.389.1948 Boehringer Ingelheim Investigational Site

City

Neuss

Country

Germany

Facility Name

205.389.1958 Boehringer Ingelheim Investigational Site

City

Neuwied

Country

Germany

Facility Name

205.389.1805 Boehringer Ingelheim Investigational Site

City

Neuötting

Country

Germany

Facility Name

205.389.1830 Boehringer Ingelheim Investigational Site

City

Niesky

Country

Germany

Facility Name

205.389.1711 Boehringer Ingelheim Investigational Site

City

Nussbach

Country

Germany

Facility Name

205.389.1781 Boehringer Ingelheim Investigational Site

City

Oberdorla

Country

Germany

Facility Name

205.389.1753 Boehringer Ingelheim Investigational Site

City

Paderborn

Country

Germany

Facility Name

205.389.1810 Boehringer Ingelheim Investigational Site

City

Paderborn

Country

Germany

Facility Name

205.389.1854 Boehringer Ingelheim Investigational Site

City

Paderborn

Country

Germany

Facility Name

205.389.1756 Boehringer Ingelheim Investigational Site

City

Pirmasens

Country

Germany

Facility Name

205.389.1794 Boehringer Ingelheim Investigational Site

City

Potsdam

Country

Germany

Facility Name

205.389.1899 Boehringer Ingelheim Investigational Site

City

Potsdam

Country

Germany

Facility Name

205.389.1842 Boehringer Ingelheim Investigational Site

City

Radebeul

Country

Germany

Facility Name

205.389.1897 Boehringer Ingelheim Investigational Site

City

Rathenow

Country

Germany

Facility Name

205.389.1950 Boehringer Ingelheim Investigational Site

City

Raubach

Country

Germany

Facility Name

205.389.1783 Boehringer Ingelheim Investigational Site

City

Riesa

Country

Germany

Facility Name

205.389.1826 Boehringer Ingelheim Investigational Site

City

Riesa

Country

Germany

Facility Name

205.389.1742 Boehringer Ingelheim Investigational Site

City

Rostock

Country

Germany

Facility Name

205.389.1816 Boehringer Ingelheim Investigational Site

City

Rüdersdorf

Country

Germany

Facility Name

205.389.1883 Boehringer Ingelheim Investigational Site

City

Rüsselsheim

Country

Germany

Facility Name

205.389.1878 Boehringer Ingelheim Investigational Site

City

Saarlouis

Country

Germany

Facility Name

205.389.1833 Boehringer Ingelheim Investigational Site

City

Schmallenberg-Grafschaft

Country

Germany

Facility Name

205.389.1973 Boehringer Ingelheim Investigational Site

City

Schmölln

Country

Germany

Facility Name

205.389.1979 Boehringer Ingelheim Investigational Site

City

Schwetzingen

Country

Germany

Facility Name

205.389.1856 Boehringer Ingelheim Investigational Site

City

Simmern

Country

Germany

Facility Name

205.389.1918 Boehringer Ingelheim Investigational Site

City

Solingen

Country

Germany

Facility Name

205.389.1822 Boehringer Ingelheim Investigational Site

City

Steinfurt

Country

Germany

Facility Name

205.389.1728 Boehringer Ingelheim Investigational Site

City

Sulzbach

Country

Germany

Facility Name

205.389.1717 Boehringer Ingelheim Investigational Site

City

Templin

Country

Germany

Facility Name

205.389.1882 Boehringer Ingelheim Investigational Site

City

Treuenbrietzen

Country

Germany

Facility Name

205.389.1745 Boehringer Ingelheim Investigational Site

City

Wallerfing

Country

Germany

Facility Name

205.389.1800 Boehringer Ingelheim Investigational Site

City

Wardenburg

Country

Germany

Facility Name

205.389.1885 Boehringer Ingelheim Investigational Site

City

Weißenhorn

Country

Germany

Facility Name

205.389.1927 Boehringer Ingelheim Investigational Site

City

Westerstede

Country

Germany

Facility Name

205.389.1825 Boehringer Ingelheim Investigational Site

City

Weyhe

Country

Germany

Facility Name

205.389.1863 Boehringer Ingelheim Investigational Site

City

Wiesbaden

Country

Germany

Facility Name

205.389.1968 Boehringer Ingelheim Investigational Site

City

Wilhelmshaven

Country

Germany

Facility Name

205.389.1807 Boehringer Ingelheim Investigational Site

City

Wilster

Country

Germany

Facility Name

205.389.1754 Boehringer Ingelheim Investigational Site

City

Wolfsburg

Country

Germany

Facility Name

205.389.1919 Boehringer Ingelheim Investigational Site

City

Wuppertal

Country

Germany

Facility Name

205.389.1898 Boehringer Ingelheim Investigational Site

City

Zerbst

Country

Germany

Facility Name

205.389.2001 Boehringer Ingelheim Investigational Site

City

Budapest

Country

Hungary

Facility Name

205.389.2005 Boehringer Ingelheim Investigational Site

City

Budapest

Country

Hungary

Facility Name

205.389.2006 Boehringer Ingelheim Investigational Site

City

Budapest

Country

Hungary

Facility Name

205.389.2009 Boehringer Ingelheim Investigational Site

City

Budapest

Country

Hungary

Facility Name

205.389.2016 Boehringer Ingelheim Investigational Site

City

Budapest

Country

Hungary

Facility Name

205.389.2018 Boehringer Ingelheim Investigational Site

City

Budapest

Country

Hungary

Facility Name

205.389.2027 Boehringer Ingelheim Investigational Site

City

Budapest

Country

Hungary

Facility Name

205.389.2007 Boehringer Ingelheim Investigational Site

City

Debrecen

Country

Hungary

Facility Name

205.389.2035 Boehringer Ingelheim Investigational Site

City

Deszk

Country

Hungary

Facility Name

205.389.2015 Boehringer Ingelheim Investigational Site

City

Dunaújváros

Country

Hungary

Facility Name

205.389.2011 Boehringer Ingelheim Investigational Site

City

Füzesabony

Country

Hungary

Facility Name

205.389.2013 Boehringer Ingelheim Investigational Site

City

Gyor

Country

Hungary

Facility Name

205.389.2028 Boehringer Ingelheim Investigational Site

City

Gyula

Country

Hungary

Facility Name

205.389.2014 Boehringer Ingelheim Investigational Site

City

Jászberény

Country

Hungary

Facility Name

205.389.2021 Boehringer Ingelheim Investigational Site

City

Kecskemét

Country

Hungary

Facility Name

205.389.2025 Boehringer Ingelheim Investigational Site

City

Komárom

Country

Hungary

Facility Name

205.389.2024 Boehringer Ingelheim Investigational Site

City

Mosdós

Country

Hungary

Facility Name

205.389.2026 Boehringer Ingelheim Investigational Site

City

Mosonmagyaróvár

Country

Hungary

Facility Name

205.389.2031 Boehringer Ingelheim Investigational Site

City

Nyíregyháza

Country

Hungary

Facility Name

205.389.2002 Boehringer Ingelheim Investigational Site

City

Pécs

Country

Hungary

Facility Name

205.389.2017 Boehringer Ingelheim Investigational Site

City

Ráckeve

Country

Hungary

Facility Name

205.389.2003 Boehringer Ingelheim Investigational Site

City

Siófok

Country

Hungary

Facility Name

205.389.2010 Boehringer Ingelheim Investigational Site

City

Szarvas

Country

Hungary

Facility Name

205.389.2019 Boehringer Ingelheim Investigational Site

City

Szentendre

Country

Hungary

Facility Name

205.389.2022 Boehringer Ingelheim Investigational Site

City

Százhalombatta

Country

Hungary

Facility Name

205.389.2030 Boehringer Ingelheim Investigational Site

City

Tatabánya

Country

Hungary

Facility Name

205.389.2029 Boehringer Ingelheim Investigational Site

City

Törökbálint

Country

Hungary

Facility Name

205.389.2020 Boehringer Ingelheim Investigational Site

City

Veszprém

Country

Hungary

Facility Name

205.389.2008 Boehringer Ingelheim Investigational Site

City

Érd

Country

Hungary

Facility Name

205.389.2101 Boehringer Ingelheim Investigational Site

City

Afula

Country

Israel

Facility Name

205.389.2110 Boehringer Ingelheim Investigational Site

City

Ashkelon

Country

Israel

Facility Name

205.389.2106 Boehringer Ingelheim Investigational Site

City

Be'er-Sheva

Country

Israel

Facility Name

205.389.2112 Boehringer Ingelheim Investigational Site

City

Hadera

Country

Israel

Facility Name

205.389.2107 Boehringer Ingelheim Investigational Site

City

Haifa

Country

Israel

Facility Name

205.389.2111 Boehringer Ingelheim Investigational Site

City

Haifa

Country

Israel

Facility Name

205.389.2108 Boehringer Ingelheim Investigational Site

City

Holon

Country

Israel

Facility Name

205.389.2104 Boehringer Ingelheim Investigational Site

City

Jerusalem

Country

Israel

Facility Name

205.389.2114 Boehringer Ingelheim Investigational Site

City

Jerusalem

Country

Israel

Facility Name

205.389.2116 Boehringer Ingelheim Investigational Site

City

Nahariya

Country

Israel

Facility Name

205.389.2102 Boehringer Ingelheim Investigational Site

City

Petah Tiqwa

Country

Israel

Facility Name

205.389.2105 Boehringer Ingelheim Investigational Site

City

Rehovot

Country

Israel

Facility Name

205.389.2103 Boehringer Ingelheim Investigational Site

City

Tel Hashomer

Country

Israel

Facility Name

205.389.2117 Boehringer Ingelheim Investigational Site

City

Zerifin

Country

Israel

Facility Name

205.389.2211 Boehringer Ingelheim Investigational Site

City

Brescia

Country

Italy

Facility Name

205.389.2206 Boehringer Ingelheim Investigational Site

City

Cagliari

Country

Italy

Facility Name

205.389.2223 Boehringer Ingelheim Investigational Site

City

Catania

Country

Italy

Facility Name

205.389.2209 Boehringer Ingelheim Investigational Site

City

Ferrara

Country

Italy

Facility Name

205.389.2214 Boehringer Ingelheim Investigational Site

City

Genova

Country

Italy

Facility Name

205.389.2215 Boehringer Ingelheim Investigational Site

City

Lecco

Country

Italy

Facility Name

205.389.2221 Boehringer Ingelheim Investigational Site

City

Milano

Country

Italy

Facility Name

205.389.2226 Boehringer Ingelheim Investigational Site

City

Milano

Country

Italy

Facility Name

205.389.2224 Boehringer Ingelheim Investigational Site

City

Modena

Country

Italy

Facility Name

205.389.2203 Boehringer Ingelheim Investigational Site

City

Montescano (PV)

Country

Italy

Facility Name

205.389.2230 Boehringer Ingelheim Investigational Site

City

Napoli

Country

Italy

Facility Name

205.389.2201 Boehringer Ingelheim Investigational Site

City

Novara

Country

Italy

Facility Name

205.389.2229 Boehringer Ingelheim Investigational Site

City

Pavia

Country

Italy

Facility Name

205.389.2227 Boehringer Ingelheim Investigational Site

City

Pisa

Country

Italy

Facility Name

205.389.2205 Boehringer Ingelheim Investigational Site

City

Roma

Country

Italy

Facility Name

205.389.2228 Boehringer Ingelheim Investigational Site

City

Roma

Country

Italy

Facility Name

205.389.2210 Boehringer Ingelheim Investigational Site

City

Sassari

Country

Italy

Facility Name

205.389.2232 Boehringer Ingelheim Investigational Site

City

Treviso

Country

Italy

Facility Name

205.389.2315 Boehringer Ingelheim Investigational Site

City

Balvi

Country

Latvia

Facility Name

205.389.2305 Boehringer Ingelheim Investigational Site

City

Daugavpils

Country

Latvia

Facility Name

205.389.2313 Boehringer Ingelheim Investigational Site

City

Jelgava

Country

Latvia

Facility Name

205.389.2311 Boehringer Ingelheim Investigational Site

City

Kraslava

Country

Latvia

Facility Name

205.389.2312 Boehringer Ingelheim Investigational Site

City

Kuldiga

Country

Latvia

Facility Name

205.389.2301 Boehringer Ingelheim Investigational Site

City

Riga

Country

Latvia

Facility Name

205.389.2303 Boehringer Ingelheim Investigational Site

City

Riga

Country

Latvia

Facility Name

205.389.2307 Boehringer Ingelheim Investigational Site

City

Riga

Country

Latvia

Facility Name

205.389.2310 Boehringer Ingelheim Investigational Site

City

Riga

Country

Latvia

Facility Name

205.389.2306 Boehringer Ingelheim Investigational Site

City

Talsi

Country

Latvia

Facility Name

205.389.2314 Boehringer Ingelheim Investigational Site

City

Tukums

Country

Latvia

Facility Name

205.389.2304 Boehringer Ingelheim Investigational Site

City

Valmiera

Country

Latvia

Facility Name

205.389.2302 Boehringer Ingelheim Investigational Site

City

Ventspils

Country

Latvia

Facility Name

205.389.2401 Boehringer Ingelheim Investigational Site

City

Alytus

Country

Lithuania

Facility Name

205.389.2402 Boehringer Ingelheim Investigational Site

City

Kaunas

Country

Lithuania

Facility Name

205.389.2403 Boehringer Ingelheim Investigational Site

City

Kaunas

Country

Lithuania

Facility Name

205.389.2404 Boehringer Ingelheim Investigational Site

City

Kaunas

Country

Lithuania

Facility Name

205.389.2406 Boehringer Ingelheim Investigational Site

City

Kaunas

Country

Lithuania

Facility Name

205.389.2409 Boehringer Ingelheim Investigational Site

City

Kaunas

Country

Lithuania

Facility Name

205.389.2407 Boehringer Ingelheim Investigational Site

City

Klaipeda

Country

Lithuania

Facility Name

205.389.2411 Boehringer Ingelheim Investigational Site

City

Klaipeda

Country

Lithuania

Facility Name

205.389.2408 Boehringer Ingelheim Investigational Site

City

Siauliai

Country

Lithuania

Facility Name

205.389.2410 Boehringer Ingelheim Investigational Site

City

Utena

Country

Lithuania

Facility Name

205.389.2405 Boehringer Ingelheim Investigational Site

City

Vilnius

Country

Lithuania

Facility Name

205.389.2412 Boehringer Ingelheim Investigational Site

City

Vilnius

Country

Lithuania

Facility Name

205.389.2413 Boehringer Ingelheim Investigational Site

City

Vilnius

Country

Lithuania

Facility Name

205.389.2414 Boehringer Ingelheim Investigational Site

City

Vilnius

Country

Lithuania

Facility Name

205.389.2504 Boehringer Ingelheim Investigational Site

City

Rotterdam

Country

Netherlands

Facility Name

205.389.2508 Boehringer Ingelheim Investigational Site

City

te Leiderdrop

Country

Netherlands

Facility Name

205.389.2510 Boehringer Ingelheim Investigational Site

City

Velp

Country

Netherlands

Facility Name

205.389.2511 Boehringer Ingelheim Investigational Site

City

Zoetermeer

Country

Netherlands

Facility Name

205.389.2614 Boehringer Ingelheim Investigational Site

City

Alesund

Country

Norway

Facility Name

205.389.2604 Boehringer Ingelheim Investigational Site

City

Bekkestua

Country

Norway

Facility Name

205.389.2601 Boehringer Ingelheim Investigational Site

City

Elverum

Country

Norway

Facility Name

205.389.2611 Boehringer Ingelheim Investigational Site

City

Follebu

Country

Norway

Facility Name

205.389.2602 Boehringer Ingelheim Investigational Site

City

Hamar

Country

Norway

Facility Name

205.389.2610 Boehringer Ingelheim Investigational Site

City

Harstad

Country

Norway

Facility Name

205.389.2613 Boehringer Ingelheim Investigational Site

City

Harstad

Country

Norway

Facility Name

205.389.2609 Boehringer Ingelheim Investigational Site

City

Hønefoss

Country

Norway

Facility Name

205.389.2608 Boehringer Ingelheim Investigational Site

City

Lørenskog

Country

Norway

Facility Name

205.389.2605 Boehringer Ingelheim Investigational Site

City

Oslo

Country

Norway

Facility Name

205.389.2612 Boehringer Ingelheim Investigational Site

City

Oslo

Country

Norway

Facility Name

205.389.2616 Boehringer Ingelheim Investigational Site

City

Stavanger

Country

Norway

Facility Name

205.389.2708 Boehringer Ingelheim Investigational Site

City

Bialystok

Country

Poland

Facility Name

205.389.2744 Boehringer Ingelheim Investigational Site

City

Bialystok

Country

Poland

Facility Name

205.389.2762 Boehringer Ingelheim Investigational Site

City

Bialystok

Country

Poland

Facility Name

205.389.2765 Boehringer Ingelheim Investigational Site

City

Bialystok

Country

Poland

Facility Name

205.389.2778 Boehringer Ingelheim Investigational Site

City

Bielsko-Biala

Country

Poland

Facility Name

205.389.2706 Boehringer Ingelheim Investigational Site

City

Bienkowka 410

Country

Poland

Facility Name

205.389.2750 Boehringer Ingelheim Investigational Site

City

Brzesko

Country

Poland

Facility Name

205.389.2758 Boehringer Ingelheim Investigational Site

City

Bydgoszcz

Country

Poland

Facility Name

205.389.2773 Boehringer Ingelheim Investigational Site

City

Bystra

Country

Poland

Facility Name

205.389.2800 Boehringer Ingelheim Investigational Site

City

Chodziez

Country

Poland

Facility Name

205.389.2712 Boehringer Ingelheim Investigational Site

City

Czestochowa

Country

Poland

Facility Name

205.389.2774 Boehringer Ingelheim Investigational Site

City

Czestochowa

Country

Poland

Facility Name

205.389.2815 Boehringer Ingelheim Investigational Site

City

Dzialdowo

Country

Poland

Facility Name

205.389.2787 Boehringer Ingelheim Investigational Site

City

Elblag

Country

Poland

Facility Name

205.389.2715 Boehringer Ingelheim Investigational Site

City

Gdansk

Country

Poland

Facility Name

205.389.2723 Boehringer Ingelheim Investigational Site

City

Gdansk

Country

Poland

Facility Name

205.389.2743 Boehringer Ingelheim Investigational Site

City

Gdansk

Country

Poland

Facility Name

205.389.2764 Boehringer Ingelheim Investigational Site

City

Gdansk

Country

Poland

Facility Name

205.389.2802 Boehringer Ingelheim Investigational Site

City

Gdansk

Country

Poland

Facility Name

205.389.2801 Boehringer Ingelheim Investigational Site

City

Gorzow Wlkp

Country

Poland

Facility Name

205.389.2805 Boehringer Ingelheim Investigational Site

City

Ilawa

Country

Poland

Facility Name

205.389.2791 Boehringer Ingelheim Investigational Site

City

Inowroclaw

Country

Poland

Facility Name

205.389.2705 Boehringer Ingelheim Investigational Site

City

Katowice

Country

Poland

Facility Name

205.389.2749 Boehringer Ingelheim Investigational Site

City

Katowice

Country

Poland

Facility Name

205.389.2771 Boehringer Ingelheim Investigational Site

City

Katowice

Country

Poland

Facility Name

205.389.2759 Boehringer Ingelheim Investigational Site

City

Koszalin

Country

Poland

Facility Name

205.389.2711 Boehringer Ingelheim Investigational Site

City

Krakow

Country

Poland

Facility Name

205.389.2722 Boehringer Ingelheim Investigational Site

City

Krakow

Country

Poland

Facility Name

205.389.2747 Boehringer Ingelheim Investigational Site

City

Krakow

Country

Poland

Facility Name

205.389.2753 Boehringer Ingelheim Investigational Site

City

Krakow

Country

Poland

Facility Name

205.389.2798 Boehringer Ingelheim Investigational Site

City

Krakow

Country

Poland

Facility Name

205.389.2748 Boehringer Ingelheim Investigational Site

City

Kraków

Country

Poland

Facility Name

205.389.2757 Boehringer Ingelheim Investigational Site

City

Kutno

Country

Poland

Facility Name

205.389.2727 Boehringer Ingelheim Investigational Site

City

Leszno

Country

Poland

Facility Name

205.389.2701 Boehringer Ingelheim Investigational Site

City

Lodz

Country

Poland

Facility Name

205.389.2709 Boehringer Ingelheim Investigational Site

City

Lodz

Country

Poland

Facility Name

205.389.2716 Boehringer Ingelheim Investigational Site

City

Lodz

Country

Poland

Facility Name

205.389.2724 Boehringer Ingelheim Investigational Site

City

Lodz

Country

Poland

Facility Name

205.389.2732 Boehringer Ingelheim Investigational Site

City

Lodz

Country

Poland

Facility Name

205.389.2746 Boehringer Ingelheim Investigational Site

City

Lodz

Country

Poland

Facility Name

205.389.2751 Boehringer Ingelheim Investigational Site

City

Lodz

Country

Poland

Facility Name

205.389.2804 Boehringer Ingelheim Investigational Site

City

Lomza

Country

Poland

Facility Name

205.389.2741 Boehringer Ingelheim Investigational Site

City

Lublin

Country

Poland

Facility Name

205.389.2776 Boehringer Ingelheim Investigational Site

City

Lublin

Country

Poland

Facility Name

205.389.2817 Boehringer Ingelheim Investigational Site

City

Lublin

Country

Poland

Facility Name

205.389.2760 Boehringer Ingelheim Investigational Site

City

Olawa

Country

Poland

Facility Name

205.389.2756 Boehringer Ingelheim Investigational Site

City

Olsztyn

Country

Poland

Facility Name

205.389.2816 Boehringer Ingelheim Investigational Site

City

Olsztyn

Country

Poland

Facility Name

205.389.2702 Boehringer Ingelheim Investigational Site

City

Ostrow Wielkopolska

Country

Poland

Facility Name

205.389.2726 Boehringer Ingelheim Investigational Site

City

Pabianice

Country

Poland

Facility Name

205.389.2795 Boehringer Ingelheim Investigational Site

City

Plawno

Country

Poland

Facility Name

205.389.2730 Boehringer Ingelheim Investigational Site

City

Plock

Country

Poland

Facility Name

205.389.2703 Boehringer Ingelheim Investigational Site

City

Poznan

Country

Poland

Facility Name

205.389.2719 Boehringer Ingelheim Investigational Site

City

Poznan

Country

Poland

Facility Name

205.389.2737 Boehringer Ingelheim Investigational Site

City

Poznan

Country

Poland

Facility Name

205.389.2766 Boehringer Ingelheim Investigational Site

City

Poznan

Country

Poland

Facility Name

205.389.2769 Boehringer Ingelheim Investigational Site

City

Poznan

Country

Poland

Facility Name

205.389.2813 Boehringer Ingelheim Investigational Site

City

Poznan

Country

Poland

Facility Name

205.389.2763 Boehringer Ingelheim Investigational Site

City

Proszowice

Country

Poland

Facility Name

205.389.2767 Boehringer Ingelheim Investigational Site

City

Pruszkow

Country

Poland

Facility Name

205.389.2768 Boehringer Ingelheim Investigational Site

City

Radom

Country

Poland

Facility Name

205.389.2792 Boehringer Ingelheim Investigational Site

City

Sandomierz

Country

Poland

Facility Name

205.389.2781 Boehringer Ingelheim Investigational Site

City

Sieradz

Country

Poland

Facility Name

205.389.2725 Boehringer Ingelheim Investigational Site

City

Skierniewice

Country

Poland

Facility Name

205.389.2777 Boehringer Ingelheim Investigational Site

City

Szczecin - Zdunowo

Country

Poland

Facility Name

205.389.2782 Boehringer Ingelheim Investigational Site

City

Szczecin - Zdunowo

Country

Poland

Facility Name

205.389.2718 Boehringer Ingelheim Investigational Site

City

Szczecin

Country

Poland

Facility Name

205.389.2739 Boehringer Ingelheim Investigational Site

City

Szczecin

Country

Poland

Facility Name

205.389.2772 Boehringer Ingelheim Investigational Site

City

Szczecin

Country

Poland

Facility Name

205.389.2738 Boehringer Ingelheim Investigational Site

City

Tarnow

Country

Poland

Facility Name

205.389.2799 Boehringer Ingelheim Investigational Site

City

Tarnow

Country

Poland

Facility Name

205.389.2810 Boehringer Ingelheim Investigational Site

City

Tczew

Country

Poland

Facility Name

205.389.2775 Boehringer Ingelheim Investigational Site

City

Torun

Country

Poland

Facility Name

205.389.2754 Boehringer Ingelheim Investigational Site

City

Tranow

Country

Poland

Facility Name

205.389.2806 Boehringer Ingelheim Investigational Site

City

Turek

Country

Poland

Facility Name

205.389.2803 Boehringer Ingelheim Investigational Site

City

Wabrzenzo

Country

Poland

Facility Name

205.389.2707 Boehringer Ingelheim Investigational Site

City

Warsaw

Country

Poland

Facility Name

205.389.2714 Boehringer Ingelheim Investigational Site

City

Warsaw

Country

Poland

Facility Name

205.389.2728 Boehringer Ingelheim Investigational Site

City

Warsaw

Country

Poland

Facility Name

205.389.2734 Boehringer Ingelheim Investigational Site

City

Warszawa

Country

Poland

Facility Name

205.389.2812 Boehringer Ingelheim Investigational Site

City

Warszawa

Country

Poland

Facility Name

205.389.2818 Boehringer Ingelheim Investigational Site

City

Warszawa

Country

Poland

Facility Name

205.389.2710 Boehringer Ingelheim Investigational Site

City

Wodzislaw Slaski

Country

Poland

Facility Name

205.389.2721 Boehringer Ingelheim Investigational Site

City

Wroclaw

Country

Poland

Facility Name

205.389.2731 Boehringer Ingelheim Investigational Site

City

Wroclaw

Country

Poland

Facility Name

205.389.2736 Boehringer Ingelheim Investigational Site

City

Wroclaw

Country

Poland

Facility Name

205.389.2752 Boehringer Ingelheim Investigational Site

City

Wroclaw

Country

Poland

Facility Name

205.389.2761 Boehringer Ingelheim Investigational Site

City

Wroclaw

Country

Poland

Facility Name

205.389.2780 Boehringer Ingelheim Investigational Site

City

Wroclaw

Country

Poland

Facility Name

205.389.2793 Boehringer Ingelheim Investigational Site

City

Wroclaw

Country

Poland

Facility Name

205.389.2783 Boehringer Ingelheim Investigational Site

City

Zabrze

Country

Poland

Facility Name

205.389.2735 Boehringer Ingelheim Investigational Site

City

Zakopane

Country

Poland

Facility Name

205.389.2770 Boehringer Ingelheim Investigational Site

City

Zgierz

Country

Poland

Facility Name

205.389.2912 Boehringer Ingelheim Investigational Site

City

Angra do Heroísmo

Country

Portugal

Facility Name

205.389.2911 Boehringer Ingelheim Investigational Site

City

Barreiro

Country

Portugal

Facility Name

205.389.2904 Boehringer Ingelheim Investigational Site

City

Faro

Country

Portugal

Facility Name

205.389.2910 Boehringer Ingelheim Investigational Site

City

Figueira da Foz

Country

Portugal

Facility Name

205.389.2907 Boehringer Ingelheim Investigational Site

City

Guarda

Country

Portugal

Facility Name

205.389.2914 Boehringer Ingelheim Investigational Site

City

Lisboa

Country

Portugal

Facility Name

205.389.2917 Boehringer Ingelheim Investigational Site

City

Lisboa

Country

Portugal

Facility Name

205.389.2905 Boehringer Ingelheim Investigational Site

City

Santa Maria da Feira

Country

Portugal

Facility Name

205.389.2909 Boehringer Ingelheim Investigational Site

City

Santiago do Cacem

Country

Portugal

Facility Name

205.389.2903 Boehringer Ingelheim Investigational Site

City

Torres Vedras

Country

Portugal

Facility Name

205.389.3009 Boehringer Ingelheim Investigational Site

City

Brasov

Country

Romania

Facility Name

205.389.3018 Boehringer Ingelheim Investigational Site

City

Brasov

Country

Romania

Facility Name

205.389.3023 Boehringer Ingelheim Investigational Site

City

Brasov

Country

Romania

Facility Name

205.389.3025 Boehringer Ingelheim Investigational Site

City

Bucharest

Country

Romania

Facility Name

205.389.3001 Boehringer Ingelheim Investigational Site

City

Bucuresti

Country

Romania

Facility Name

205.389.3002 Boehringer Ingelheim Investigational Site

City

Bucuresti

Country

Romania

Facility Name

205.389.3004 Boehringer Ingelheim Investigational Site

City

Bucuresti

Country

Romania

Facility Name

205.389.3006 Boehringer Ingelheim Investigational Site

City

Bucuresti

Country

Romania

Facility Name

205.389.3007 Boehringer Ingelheim Investigational Site

City

Bucuresti

Country

Romania

Facility Name

205.389.3012 Boehringer Ingelheim Investigational Site

City

Bucuresti

Country

Romania

Facility Name

205.389.3013 Boehringer Ingelheim Investigational Site

City

Bucuresti

Country

Romania

Facility Name

205.389.3016 Boehringer Ingelheim Investigational Site

City

Constanta

Country

Romania

Facility Name

205.389.3019 Boehringer Ingelheim Investigational Site

City

Constanta

Country

Romania

Facility Name

205.389.3015 Boehringer Ingelheim Investigational Site

City

Craiova

Country

Romania

Facility Name

205.389.3008 Boehringer Ingelheim Investigational Site

City

Iasi

Country

Romania

Facility Name

205.389.3014 Boehringer Ingelheim Investigational Site

City

Iasi

Country

Romania

Facility Name

205.389.3022 Boehringer Ingelheim Investigational Site

City

Iasi

Country

Romania

Facility Name

205.389.3024 Boehringer Ingelheim Investigational Site

City

Iasi

Country

Romania

Facility Name

205.389.3005 Boehringer Ingelheim Investigational Site

City

Oradea

Country

Romania

Facility Name

205.389.3017 Boehringer Ingelheim Investigational Site

City

Tg. Mures

Country

Romania

Facility Name

205.389.3021 Boehringer Ingelheim Investigational Site

City

Timisoara

Country

Romania

Facility Name

205.389.3174 Boehringer Ingelheim Investigational Site

City

Arkhangelsk

Country

Russian Federation

Facility Name

205.389.3113 Boehringer Ingelheim Investigational Site

City

Barnaul

Country

Russian Federation

Facility Name

205.389.3131 Boehringer Ingelheim Investigational Site

City

Barnaul

Country

Russian Federation

Facility Name

205.389.3105 Boehringer Ingelheim Investigational Site

City

Chelyabinsk

Country

Russian Federation

Facility Name

205.389.3182 Boehringer Ingelheim Investigational Site

City

Chelyabinsk

Country

Russian Federation

Facility Name

205.389.3183 Boehringer Ingelheim Investigational Site

City

Chelyabinsk

Country

Russian Federation

Facility Name

205.389.3184 Boehringer Ingelheim Investigational Site

City

Chelyabinsk

Country

Russian Federation

Facility Name

205.389.3116 Boehringer Ingelheim Investigational Site

City

Ekaterinburg

Country

Russian Federation

Facility Name

205.389.3138 Boehringer Ingelheim Investigational Site

City

Ekaterinburg

Country

Russian Federation

Facility Name

205.389.3148 Boehringer Ingelheim Investigational Site

City

Ekaterinburg

Country

Russian Federation

Facility Name

205.389.3166 Boehringer Ingelheim Investigational Site

City

Ekaterinburg

Country

Russian Federation

Facility Name

205.389.3186 Boehringer Ingelheim Investigational Site

City

Gatchina (Leningradskaya oblast)

Country

Russian Federation

Facility Name

205.389.3193 Boehringer Ingelheim Investigational Site

City

Kaliningrad

Country

Russian Federation

Facility Name

205.389.3104 Boehringer Ingelheim Investigational Site

City

Kazan

Country

Russian Federation

Facility Name

205.389.3111 Boehringer Ingelheim Investigational Site

City

Kemerovo

Country

Russian Federation

Facility Name

205.389.3120 Boehringer Ingelheim Investigational Site

City

Kirov

Country

Russian Federation

Facility Name

205.389.3170 Boehringer Ingelheim Investigational Site

City

Krasnodar

Country

Russian Federation

Facility Name

205.389.3132 Boehringer Ingelheim Investigational Site

City

Krasnoyarsk

Country

Russian Federation

Facility Name

205.389.3103 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3106 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3107 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3108 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3109 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3125 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3127 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3128 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3130 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3134 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3136 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3139 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3140 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3143 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3149 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3151 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3156 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3157 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3163 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3164 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3167 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3168 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3171 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3196 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.389.3188 Boehringer Ingelheim Investigational Site

City

Murmansk

Country

Russian Federation

Facility Name

205.389.3953 Boehringer Ingelheim Investigational Site

City

Nizhniy Novgorod

Country

Russian Federation

Facility Name

205.389.3169 Boehringer Ingelheim Investigational Site

City

Nizhny Novgorod

Country

Russian Federation

Facility Name

205.389.3112 Boehringer Ingelheim Investigational Site

City

Novosibirsk

Country

Russian Federation

Facility Name

205.389.3114 Boehringer Ingelheim Investigational Site

City

Novosibirsk

Country

Russian Federation

Facility Name

205.389.3129 Boehringer Ingelheim Investigational Site

City

Novosibirsk

Country

Russian Federation

Facility Name

205.389.3141 Boehringer Ingelheim Investigational Site

City

Novosibirsk

Country

Russian Federation

Facility Name

205.389.3153 Boehringer Ingelheim Investigational Site

City

Novosibirsk

Country

Russian Federation

Facility Name

205.389.3175 Boehringer Ingelheim Investigational Site

City

Novosibirsk

Country

Russian Federation

Facility Name

205.389.3126 Boehringer Ingelheim Investigational Site

City

Orenburg

Country

Russian Federation

Facility Name

205.389.3185 Boehringer Ingelheim Investigational Site

City

Perm

Country

Russian Federation

Facility Name

205.389.3192 Boehringer Ingelheim Investigational Site

City

Petrozavodsk

Country

Russian Federation

Facility Name

205.389.3179 Boehringer Ingelheim Investigational Site

City

Pskov

Country

Russian Federation

Facility Name

205.389.3190 Boehringer Ingelheim Investigational Site

City

Pskov

Country

Russian Federation

Facility Name

205.389.3199 Boehringer Ingelheim Investigational Site

City

Pyatigorsk,

Country

Russian Federation

Facility Name

205.389.3159 Boehringer Ingelheim Investigational Site

City

Rostov-on-Don

Country

Russian Federation

Facility Name

205.389.3197 Boehringer Ingelheim Investigational Site

City

Ryazan

Country

Russian Federation

Facility Name

205.389.3198 Boehringer Ingelheim Investigational Site

City

Saint Petersburg

Country

Russian Federation

Facility Name

205.389.3110 Boehringer Ingelheim Investigational Site

City

Saratov

Country

Russian Federation

Facility Name

205.389.3951 Boehringer Ingelheim Investigational Site

City

Saratov

Country

Russian Federation

Facility Name

205.389.3191 Boehringer Ingelheim Investigational Site

City

St-Petersburg

Country

Russian Federation

Facility Name

205.389.3119 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3121 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3122 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3123 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3135 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3137 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3145 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3146 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3160 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3161 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3176 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3177 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3178 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3180 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3181 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3189 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3195 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3950 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.389.3165 Boehringer Ingelheim Investigational Site

City

St.Peterburg

Country

Russian Federation

Facility Name

205.389.3117 Boehringer Ingelheim Investigational Site

City

St.Petersburg

Country

Russian Federation

Facility Name

205.389.3147 Boehringer Ingelheim Investigational Site

City

St.Petersburg

Country

Russian Federation

Facility Name

205.389.3152 Boehringer Ingelheim Investigational Site

City

St.Petersburg

Country

Russian Federation

Facility Name

205.389.3101 Boehringer Ingelheim Investigational Site

City

Tomsk

Country

Russian Federation

Facility Name

205.389.3102 Boehringer Ingelheim Investigational Site

City

Tomsk

Country

Russian Federation

Facility Name

205.389.3133 Boehringer Ingelheim Investigational Site

City

Tomsk

Country

Russian Federation

Facility Name

205.389.3144 Boehringer Ingelheim Investigational Site

City

Tomsk

Country

Russian Federation

Facility Name

205.389.3194 Boehringer Ingelheim Investigational Site

City

Velikiy Novgorod

Country

Russian Federation

Facility Name

205.389.3118 Boehringer Ingelheim Investigational Site

City

Yaroslavl

Country

Russian Federation

Facility Name

205.389.3155 Boehringer Ingelheim Investigational Site

City

Yaroslavl

Country

Russian Federation

Facility Name

205.389.3208 Boehringer Ingelheim Investigational Site

City

Bratislava

Country

Slovakia

Facility Name

205.389.3204 Boehringer Ingelheim Investigational Site

City

Kosice

Country

Slovakia

Facility Name

205.389.3209 Boehringer Ingelheim Investigational Site

City

Kosice

Country

Slovakia

Facility Name

205.389.3205 Boehringer Ingelheim Investigational Site

City

Prievidza

Country

Slovakia

Facility Name

205.389.3210 Boehringer Ingelheim Investigational Site

City

Revuca

Country

Slovakia

Facility Name

205.389.3203 Boehringer Ingelheim Investigational Site

City

Spisska Nova Ves

Country

Slovakia

Facility Name

205.389.3202 Boehringer Ingelheim Investigational Site

City

Trnava

Country

Slovakia

Facility Name

205.389.3207 Boehringer Ingelheim Investigational Site

City

Vrable

Country

Slovakia

Facility Name

205.389.3301 Boehringer Ingelheim Investigational Site

City

Golnik

Country

Slovenia

Facility Name

205.389.3308 Boehringer Ingelheim Investigational Site

City

Grosuplje

Country

Slovenia

Facility Name

205.389.3304 Boehringer Ingelheim Investigational Site

City

Jesenice

Country

Slovenia

Facility Name

205.389.3302 Boehringer Ingelheim Investigational Site

City

Kamnik

Country

Slovenia

Facility Name

205.389.3303 Boehringer Ingelheim Investigational Site

City

Ljubljana

Country

Slovenia

Facility Name

205.389.3306 Boehringer Ingelheim Investigational Site

City

Topolsica

Country

Slovenia

Facility Name

205.389.3410 Boehringer Ingelheim Investigational Site

City

Badajoz

Country

Spain

Facility Name

205.389.3403 Boehringer Ingelheim Investigational Site

City

Badalona (Barcelona)

Country

Spain

Facility Name

205.389.3401 Boehringer Ingelheim Investigational Site

City

Barcelona

Country

Spain

Facility Name

205.389.3402 Boehringer Ingelheim Investigational Site

City

Barcelona

Country

Spain

Facility Name

205.389.3428 Boehringer Ingelheim Investigational Site

City

Barcelona

Country

Spain

Facility Name

205.389.3430 Boehringer Ingelheim Investigational Site

City

Cartagena

Country

Spain

Facility Name

205.389.3416 Boehringer Ingelheim Investigational Site

City

Cáceres

Country

Spain

Facility Name

205.389.3425 Boehringer Ingelheim Investigational Site

City

Elche

Country

Spain

Facility Name

205.389.3408 Boehringer Ingelheim Investigational Site

City

Las Palmas de Gran Canarias

Country

Spain

Facility Name

205.389.3405 Boehringer Ingelheim Investigational Site

City

Lleida

Country

Spain

Facility Name

205.389.3404 Boehringer Ingelheim Investigational Site

City

Madrid

Country

Spain

Facility Name

205.389.3406 Boehringer Ingelheim Investigational Site

City

Madrid

Country

Spain

Facility Name

205.389.3414 Boehringer Ingelheim Investigational Site

City

Málaga

Country

Spain

Facility Name

205.389.3431 Boehringer Ingelheim Investigational Site

City

Pontevedra

Country

Spain

Facility Name

205.389.3419 Boehringer Ingelheim Investigational Site

City

Requena

Country

Spain

Facility Name

205.389.3427 Boehringer Ingelheim Investigational Site

City

Reus

Country

Spain

Facility Name

205.389.3422 Boehringer Ingelheim Investigational Site

City

Sagunto

Country

Spain

Facility Name

205.389.3420 Boehringer Ingelheim Investigational Site

City

San Juan

Country

Spain

Facility Name

205.389.3415 Boehringer Ingelheim Investigational Site

City

Santander

Country

Spain

Facility Name

205.389.3421 Boehringer Ingelheim Investigational Site

City

Santiago de Compostela

Country

Spain

Facility Name

205.389.3407 Boehringer Ingelheim Investigational Site

City

Terrasa (Barcelona)

Country

Spain

Facility Name

205.389.3413 Boehringer Ingelheim Investigational Site

City

Valencia

Country

Spain

Facility Name

205.389.3426 Boehringer Ingelheim Investigational Site

City

Valencia

Country

Spain

Facility Name

205.389.3417 Boehringer Ingelheim Investigational Site

City

Valladolid

Country

Spain

Facility Name

205.389.3821 Boehringer Ingelheim Investigational Site

City

Adana

Country

Turkey

Facility Name

205.389.3808 Boehringer Ingelheim Investigational Site

City

Ankara

Country

Turkey

Facility Name

205.389.3810 Boehringer Ingelheim Investigational Site

City

Ankara

Country

Turkey

Facility Name

205.389.3817 Boehringer Ingelheim Investigational Site

City

Bursa

Country

Turkey

Facility Name

205.389.3819 Boehringer Ingelheim Investigational Site

City

Erzurum

Country

Turkey

Facility Name

205.389.3812 Boehringer Ingelheim Investigational Site

City

Istanbul

Country

Turkey

Facility Name

205.389.3827 Boehringer Ingelheim Investigational Site

City

Izmir

Country

Turkey

Facility Name

205.389.3813 Boehringer Ingelheim Investigational Site

City

Izmit

Country

Turkey

Facility Name

205.389.3820 Boehringer Ingelheim Investigational Site

City

Kahramanmaras

Country

Turkey

Facility Name

205.389.3825 Boehringer Ingelheim Investigational Site

City

Malatya

Country

Turkey

Facility Name

205.389.3809 Boehringer Ingelheim Investigational Site

City

Sihhiye Ankara

Country

Turkey

Facility Name

205.389.3807 Boehringer Ingelheim Investigational Site

City

Yenisehir-IZMIR

Country

Turkey

Facility Name

205.389.3521 Boehringer Ingelheim Investigational Site

City

AR Crimea

Country

Ukraine

Facility Name

205.389.3516 Boehringer Ingelheim Investigational Site

City

Cherkassy

Country

Ukraine

Facility Name

205.389.3549 Boehringer Ingelheim Investigational Site

City

Chernivtsi

Country

Ukraine

Facility Name

205.389.3509 Boehringer Ingelheim Investigational Site

City

Dnipropetrovsk

Country

Ukraine

Facility Name

205.389.3510 Boehringer Ingelheim Investigational Site

City

Dnipropetrovsk

Country

Ukraine

Facility Name

205.389.3511 Boehringer Ingelheim Investigational Site

City

Dnipropetrovsk

Country

Ukraine

Facility Name

205.389.3523 Boehringer Ingelheim Investigational Site

City

Dnipropetrovsk

Country

Ukraine

Facility Name

205.389.3514 Boehringer Ingelheim Investigational Site

City

Donetsk

Country

Ukraine

Facility Name

205.389.3524 Boehringer Ingelheim Investigational Site

City

Donetsk

Country

Ukraine

Facility Name

205.389.3533 Boehringer Ingelheim Investigational Site

City

Ivano-Frankivsk

Country

Ukraine

Facility Name

205.389.3506 Boehringer Ingelheim Investigational Site

City

Kharkiv

Country

Ukraine

Facility Name

205.389.3507 Boehringer Ingelheim Investigational Site

City

Kharkiv

Country

Ukraine

Facility Name

205.389.3508 Boehringer Ingelheim Investigational Site

City

Kharkiv

Country

Ukraine

Facility Name

205.389.3520 Boehringer Ingelheim Investigational Site

City

Kharkiv

Country

Ukraine

Facility Name

205.389.3522 Boehringer Ingelheim Investigational Site

City

Kharkiv

Country

Ukraine

Facility Name

205.389.3532 Boehringer Ingelheim Investigational Site

City

Kharkiv

Country

Ukraine

Facility Name

205.389.3539 Boehringer Ingelheim Investigational Site

City

Kharkiv

Country

Ukraine

Facility Name

205.389.3541 Boehringer Ingelheim Investigational Site

City

Kharkiv

Country

Ukraine

Facility Name

205.389.3543 Boehringer Ingelheim Investigational Site

City

Kharkiv

Country

Ukraine

Facility Name

205.389.3555 Boehringer Ingelheim Investigational Site

City

Kharkiv

Country

Ukraine

Facility Name

205.389.3501 Boehringer Ingelheim Investigational Site

City

Kiev

Country

Ukraine

Facility Name

205.389.3502 Boehringer Ingelheim Investigational Site

City

Kiev

Country

Ukraine

Facility Name

205.389.3503 Boehringer Ingelheim Investigational Site

City

Kiev

Country

Ukraine

Facility Name

205.389.3550 Boehringer Ingelheim Investigational Site

City

Kiev

Country

Ukraine

Facility Name

205.389.3552 Boehringer Ingelheim Investigational Site

City

Kiev

Country

Ukraine

Facility Name

205.389.3553 Boehringer Ingelheim Investigational Site

City

Kiev

Country

Ukraine

Facility Name

205.389.3504 Boehringer Ingelheim Investigational Site

City

Kyiv

Country

Ukraine

Facility Name

205.389.3525 Boehringer Ingelheim Investigational Site

City

Kyiv

Country

Ukraine

Facility Name

205.389.3526 Boehringer Ingelheim Investigational Site

City

Kyiv

Country

Ukraine

Facility Name

205.389.3528 Boehringer Ingelheim Investigational Site

City

Kyiv

Country

Ukraine

Facility Name

205.389.3534 Boehringer Ingelheim Investigational Site

City

Kyiv

Country

Ukraine

Facility Name

205.389.3535 Boehringer Ingelheim Investigational Site

City

Kyiv

Country

Ukraine

Facility Name

205.389.3536 Boehringer Ingelheim Investigational Site

City

Kyiv

Country

Ukraine

Facility Name

205.389.3538 Boehringer Ingelheim Investigational Site

City

Kyiv

Country

Ukraine

Facility Name

205.389.3551 Boehringer Ingelheim Investigational Site

City

Kyiv

Country

Ukraine

Facility Name

205.389.3545 Boehringer Ingelheim Investigational Site

City

Lugansk

Country

Ukraine

Facility Name

205.389.3512 Boehringer Ingelheim Investigational Site

City

Lviv

Country

Ukraine

Facility Name

205.389.3530 Boehringer Ingelheim Investigational Site

City

Lviv

Country

Ukraine

Facility Name

205.389.3540 Boehringer Ingelheim Investigational Site

City

Lviv

Country

Ukraine

Facility Name

205.389.3554 Boehringer Ingelheim Investigational Site

City

Lviv

Country

Ukraine

Facility Name

205.389.3556 Boehringer Ingelheim Investigational Site

City

m.Donetsk

Country

Ukraine

Facility Name

205.389.3513 Boehringer Ingelheim Investigational Site

City

m.Odesa

Country

Ukraine

Facility Name

205.389.3519 Boehringer Ingelheim Investigational Site

City

Odesa

Country

Ukraine

Facility Name

205.389.3542 Boehringer Ingelheim Investigational Site

City

Odesa

Country

Ukraine

Facility Name

205.389.3527 Boehringer Ingelheim Investigational Site

City

Odessa

Country

Ukraine

Facility Name

205.389.3531 Boehringer Ingelheim Investigational Site

City

Poltava

Country

Ukraine

Facility Name

205.389.3517 Boehringer Ingelheim Investigational Site

City

Simferopil

Country

Ukraine

Facility Name

205.389.3518 Boehringer Ingelheim Investigational Site

City

Ternopil

Country

Ukraine

Facility Name

205.389.3529 Boehringer Ingelheim Investigational Site

City

Vinnitsa

Country

Ukraine

Facility Name

205.389.3515 Boehringer Ingelheim Investigational Site

City

Zaporizhzhya

Country

Ukraine

Facility Name

205.389.3547 Boehringer Ingelheim Investigational Site

City

Zaporizhzhya

Country

Ukraine

Facility Name

205.389.3548 Boehringer Ingelheim Investigational Site

City

Zaporizhzhya

Country

Ukraine

Facility Name

205.389.3601 Boehringer Ingelheim Investigational Site

City

Bath

Country

United Kingdom

Facility Name

205.389.3630 Boehringer Ingelheim Investigational Site

City

Bexhill on Sea

Country

United Kingdom

Facility Name

205.389.3636 Boehringer Ingelheim Investigational Site

City

Bexhill-on-Sea

Country

United Kingdom

Facility Name

205.389.3608 Boehringer Ingelheim Investigational Site

City

Birmingham

Country

United Kingdom

Facility Name

205.389.3605 Boehringer Ingelheim Investigational Site

City

Blackburn

Country

United Kingdom

Facility Name

205.389.3609 Boehringer Ingelheim Investigational Site

City

Bolton

Country

United Kingdom

Facility Name

205.389.3640 Boehringer Ingelheim Investigational Site

City

Burbage

Country

United Kingdom

Facility Name

205.389.3643 Boehringer Ingelheim Investigational Site

City

Chesterfield

Country

United Kingdom

Facility Name

205.389.3627 Boehringer Ingelheim Investigational Site

City

Corsham

Country

United Kingdom

Facility Name

205.389.3606 Boehringer Ingelheim Investigational Site

City

Coventry

Country

United Kingdom

Facility Name

205.389.3633 Boehringer Ingelheim Investigational Site

City

Coventry

Country

United Kingdom

Facility Name

205.389.3639 Boehringer Ingelheim Investigational Site

City

Frome

Country

United Kingdom

Facility Name

205.389.3602 Boehringer Ingelheim Investigational Site

City

Glasgow

Country

United Kingdom

Facility Name

205.389.3632 Boehringer Ingelheim Investigational Site

City

Irvine

Country

United Kingdom

Facility Name

205.389.3623 Boehringer Ingelheim Investigational Site

City

London

Country

United Kingdom

Facility Name

205.389.3638 Boehringer Ingelheim Investigational Site

City

Middlesex

Country

United Kingdom

Facility Name

205.389.3616 Boehringer Ingelheim Investigational Site

City

Newcastle upon Tyne

Country

United Kingdom

Facility Name

205.389.3618 Boehringer Ingelheim Investigational Site

City

Paisley

Country

United Kingdom

Facility Name

205.389.3622 Boehringer Ingelheim Investigational Site

City

Radstock

Country

United Kingdom

Facility Name

205.389.3626 Boehringer Ingelheim Investigational Site

City

Randalstown

Country

United Kingdom

Facility Name

205.389.3604 Boehringer Ingelheim Investigational Site

City

Soham

Country

United Kingdom

Facility Name

205.389.3613 Boehringer Ingelheim Investigational Site

City

St Just, Penzance

Country

United Kingdom

Facility Name

205.389.3624 Boehringer Ingelheim Investigational Site

City

Sunderland

Country

United Kingdom

Facility Name

205.389.3635 Boehringer Ingelheim Investigational Site

City

Wansford, Peterborough

Country

United Kingdom

Facility Name

205.389.3631 Boehringer Ingelheim Investigational Site

City

Windsor

Country

United Kingdom

Facility Name

205.389.3612 Boehringer Ingelheim Investigational Site

City

Wrexham

Country

United Kingdom

12. IPD Sharing Statement

Citations:

PubMed Identifier

26100349

Citation

Vogelmeier CF, Asijee GM, Kupas K, Beeh KM. Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD((R)). Adv Ther. 2015 Jun;32(6):537-47. doi: 10.1007/s12325-015-0216-2. Epub 2015 Jun 23.

Results Reference

derived

PubMed Identifier

24461901

Citation

Rabe KF, Fabbri LM, Israel E, Kogler H, Riemann K, Schmidt H, Glaab T, Vogelmeier CF. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir Med. 2014 Jan;2(1):44-53. doi: 10.1016/S2213-2600(13)70248-0. Epub 2013 Dec 5.

Results Reference

derived

PubMed Identifier

24168767

Citation

Beeh KM, Glaab T, Stowasser S, Schmidt H, Fabbri LM, Rabe KF, Vogelmeier CF. Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res. 2013 Oct 29;14(1):116. doi: 10.1186/1465-9921-14-116.

Results Reference

derived

PubMed Identifier

23188489

Citation

Rabe KF, Fabbri LM, Vogelmeier C, Kogler H, Schmidt H, Beeh KM, Glaab T. Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial. Chest. 2013 Mar;143(3):711-719. doi: 10.1378/chest.12-1277.

Results Reference

derived

PubMed Identifier

21428765

Citation

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.

Results Reference

derived

PubMed Identifier

19436693

Citation

Beeh KM, Hederer B, Glaab T, Muller A, Rutten-van Moelken M, Kesten S, Vogelmeier C. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis. 2009;4:119-25. Epub 2009 Apr 15.

Results Reference

derived

Links:

URL

http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.389_U10-2159.pdf

Description

Related Info

Learn more about this trial

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

We'll reach out to this number within 24 hrs

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

Pulmonary Disease, Chronic Obstructive

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial